Modulation of H2S metabolism by statins: A new aspect of cardiovascular pharmacology

Antioxidants and Redox Signaling

Volumn 17, Issue 1, 2012, Pages 81-94

  Bełtowski, Jerzy ^a   Jamroz Wiśniewska, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROGEN SULFIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADIPOSE TISSUE; ALZHEIMER DISEASE; APOPTOSIS; BRAIN DISEASE; CARBOHYDRATE METABOLISM; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL SYNTHESIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG URINE LEVEL; ELECTRON TRANSPORT; FEEDBACK SYSTEM; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIPID METABOLISM; LIPOLYSIS; LIVER MITOCHONDRION; LIVER TOXICITY; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; MULTIPLE SCLEROSIS; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; UPREGULATION; VASODILATATION;

ANIMALS; HUMANS; HYDROGEN SULFIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; REPERFUSION INJURY;

EID: 84860704711     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4358     Document Type: Review

References (80)

1. Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, Bhatia M, and Moore PK. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulfide? Br J Pharmacol 149: 625-634, 2006.
2. Al-Magableh MR and Hart JL. Mechanism of vasorelaxation and role of endogenous hydrogen sulfide production in mouse aorta. Naunyn Schmiedebergs Arch Pharmacol 383: 403-413, 2011.
3. Bearden SE, Beard RS, and Pfau JC. Extracellular transsulfuration generates hydrogen sulfide from homocysteine and protects endothelium from redox stress. Am J Physiol Heart Circ Physiol 299: H1568-H1576, 2010.
4. Beltowski J, Jamroz-Wiśniewska A, and Tokarzewska D. Hydrogen sulfide and its modulation in arterial hypertension and atherosclerosis. Cardiovasc Hematol Agents Med Chem 8: 173-186, 2010.
5. Beltowski J, Wójcicka G, and Jamroz-Wiśniewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 4: 209-228, 2009.
6. Blum A and Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203: 325-330, 2009.
7. Bos EM, Leuvenink HG, Snijder PM, Kloosterhuis NJ, Hillebrands JL, Leemans JC, Florquin S, and van Goor H. Hydrogen sulfide-induced hypometabolism prevents renal ischemia/reperfusion injury. J Am Soc Nephrol 20: 1901-1905, 2009.
8. Bouillaud F and Blachier F. Mitochondria and sulfide: a very old story of poisoning, feeding, and signaling? Antioxid Redox Signal 15: 379-391, 2011.
9. Calvert JW, Coetzee WA, and Lefer DJ. Novel insights into hydrogen sulfide-mediated cytoprotection. Antioxid Redox Signal 12: 1203-1217, 2010.
10. Cheang WS, Wong WT, Shen B, Lau CW, Tian XY, Tsang SY, Yao X, Chen ZY, and Huang Y. 4-aminopyridinesensitive K+ channels contributes to NaHS-induced membrane hyperpolarization and relaxation in the rat coronary artery. Vascul Pharmacol 53: 94-98, 2010.
11. Cheng Y, Ndisang JF, Tang G, Cao K, and Wang R. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physio 287: H2316-H2323, 2004.
12. Chiku T, Padovani D, Zhu W, Singh S, Vitvitsky V, and Banerjee R. H2S biogenesis by human cystathionine gammalyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. J Biol Chem 284: 11601-11612, 2009.
13. Chylińska B. Effect of pravastatin and atorvastatin on synthesis and metabolism of endogenous hydrogen sulfide in the vascular wall. Ph.D. Dissertation, Medical University, Lublin, 2011.
14. d'Emmanuele di Villa Bianca R, Sorrentino R, Coletta C, Mitidieri E, Rossi A, Vellecco V, Pinto A, Cirino G, and Sorrentino R. Hydrogen sulfide-induced dual vascular effect involves arachidonic acid cascade in rat mesenteric arterial bed. J Pharmacol Exp Ther 337: 59-64, 2011.
15. Diebold BA, Bhagavan NV, and Guillory RJ. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. Biochim Biophys Acta 1200: 100-108, 1994.
16. Duncan AJ, Hargreaves IP, Damian MS, Land JM, and Heales SJ. Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment. Toxicol Mech Methods 19: 44-50, 2009.
17. Fang L, Zhao J, Chen Y, Ma T, Xu G, Tang C, Liu X, and Geng B. Hydrogen sulfide derived from periadventitial adipose tissue is a vasodilator. J Hypertens 27: 2174-2185, 2009.
18. Feng X, Chen Y, Zhao J, Tang C, Jiang Z, and Geng B. Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator. Biochem Biophys Res Commun 380: 153-159, 2009.
19. Hamadmad SN and Hohl RJ. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochem Pharmacol 74: 590-600, 2007.
20. Hildebrandt TM and Grieshaber MK. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J 275: 3352-3361, 2008.
21. Ishii I, Akahoshi N, Yamada H, Nakano S, Izumi T, and Suematsu M. Cystathionine c-lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. J Biol Chem 285: 26358-26368, 2010.
22. Istvan ES and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292: 1160-1164, 2001.
23. Jackson-Weaver O, Paredes DA, Bosc LV, Walker BR, and Kanagy NL. Intermittent hypoxia in rats increases myogenic tone through loss of hydrogen sulfide activation of largeconductance Ca2 +-activated potassium channels. Circ Res 108: 1439-1447, 2011.
24. Jiang B, Tang G, Cao K, Wu L, and Wang R. Molecular mechanism for H2S-induced activation of KATP channels. Antioxid Redox Signal 12: 1167-1178, 2010.
25. Kimura Y, Goto Y, and Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal 12: 1-13, 2010.
26. Koh KK, Sakuma I, and Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 215: 1-8, 2010
27. Kostapanos MS, Liamis GL, Milionis HJ, and Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 8: 612-631, 2010.
28. Krause BR and Newton RS Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceridelowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 117: 237-244, 1995.
29. Kromer A and Moosmann B. Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways. Mol Pharmacol 75: 1421-1429, 2009.
30. Laggner H, Hermann M, Esterbauer H, Muellner MK, Exner M, Gmeiner BM, and Kapiotis S. The novel gaseous vasorelaxant hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial cells. J Hypertens 25: 2100-2104, 2007.
31. Laggner H, Muellner MK, Schreier S, Sturm B, Hermann M, Exner M, Gmeiner BM, and Kapiotis S. Hydrogen sulfide: a novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radic Res 41: 741-747, 2007.
32. Lagoutte E, Mimoun S, Andriamihaja M, Chaumontet C, Blachier F, and Bouillaud F. Oxidation of hydrogen sulfide remains a priority in mammalian cells and causes reverse electron transfer in colonocytes. Biochim Biophys Acta 1797: 1500-1511, 2010.
33. Lenaz G and Genova ML. Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject. Antioxid Redox Signal 12: 961-1008, 2010.
34. Levitt MD, Abdel-Rehim MS, and Furne J. Free and acidlabile hydrogen sulfide concentrations in mouse tissues: anomalously high free hydrogen sulfide in aortic tissue. Antioxid Redox Signal 15: 373-378, 2011.
35. Li W, Tang C, Jin H, and Du J. Regulatory effects of sulfur dioxide on the development of atherosclerotic lesions and vascular hydrogen sulfide in atherosclerotic rats. Atherosclerosis 215: 323-330, 2011.
36. Li L, Whiteman M, Guan YY, Neo KL, Cheng Y, Lee SW, Zhao Y, Baskar R, Tan CH, and Moore PK. Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 117: 2351-2360, 2008.
37. Liu YH and Bian JS. Bicarbonate-dependent effect of hydrogen sulfide on vascular contractility in rat aortic rings. Am J Physiol Cell Physiol 299: C866-C872, 2010.
38. Löhn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, and Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J 16: 1057-1063, 2002.
39. Lu M, Liu YH, Goh HS, Wang JJ, Yong QC, Wang R, and Bian JS. Hydrogen sulfide inhibits plasma renin activity. J Am Soc Nephrol 21: 993-1002, 2010.
40. Mancuso M, Orsucci D, Volpi L, Calsolaro V, and Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets 11: 111-121, 2010.
41. Meng QH, Yang G, Yang W, Jiang B, Wu L, and Wang R. Protective effect of hydrogen sulfide on balloon injuryinduced neointima hyperplasia in rat carotid arteries. Am J Pathol 170: 1406-1414, 2007.
42. Moosmann B and Behl C. Selenoproteins, cholesterollowering drugs, and the consequences: revisiting of the mevalonate pathway. Trends Cardiovasc Med 14: 273-281, 2004.
43. Muellner MK, Schreier SM, Laggner H, Hermann M, Esterbauer H, Exner M, Gmeiner BM, and Kapiotis S. Hydrogen sulfide destroys lipid hydroperoxides in oxidized LDL. Biochem J 420: 277-281, 2009.
44. Muzaffar S; Shukla N, Bond M, Newby AC, Angelini GD, Sparatore A, Del Soldato P, and Jeremy JY. Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac1 activity in human vascular smooth muscle cells. J Vasc Res 45: 521-528, 2008.
45. Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J, Higuchi I, and Osame M. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 152: 99-106, 1998.
46. Olson KR and Whitfield NL. Hydrogen sulfide and oxygen sensing in the cardiovascular system. Antioxid Redox Signal 12: 1219-1234, 2010.
47. Olson KR, Whitfield NL, Bearden SE, St Leger J, Nilson E, Gao Y, and Madden JA. Hypoxic pulmonary vasodilation: a paradigm shift with a hydrogen sulfide mechanism. Am J Physiol Regul Integr Comp Physiol 298: R51-R60, 2010.
48. PäiväH, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, Laakso J, Lehtimäki T, von Bergmann K, Lütjohann D, and Laaksonen R. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 78: 60-68, 2005.
49. Pan LL, Liu XH, Gong QH, Wu D, and Zhu YZ. Hydrogen sulfide attenuated tumor necrosis factor-a-induced inflammatory signaling and dysfunction in vascular endothelial cells. PLoS One 6: e19766, 2011.
50. Rajsheker S, Manka D, Blomkalns AL, Chatterjee TK, Stoll LL, and Weintraub NL. Crosstalk between perivascular adipose tissue and blood vessels. Curr Opin Pharmacol 10: 191-196, 2010.
51. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, and Gotto AM. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959-1965, 2001.
52. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009, 1996.
53. Schick BA, Laaksonen R, Frohlich JJ, PäiväH, Lehtimäki T, Humphries KH, and CôtéHC. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 81: 650-653, 2007.
54. Schleifenbaum J, Köhn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, Crean CS, Luft FC, Huang Y, Schubert R, and Gollasch M. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens 28: 1875-1882, 2010.
55. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, and Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian CardiacOutcomes Trial-Lipid LoweringArm(ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003.
56. Shahak Y, Arieli B, Padan E, and Hauska G. Sulfide quinone reductase (SQR) activity in Chlorobium. FEBS Lett 299: 127-130, 1992.
57. Shibuya N, Mikami Y, Kimura Y, Nagahara N, and Kimura H. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. J Biochem 146: 623-626, 2009.
58. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, and Kimura H. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid Redox Signal 11: 703-714, 2009.
59. Shitara Y and Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112: 71-105, 2006.
60. Siddals KW, Marshman E, Westwood M, and Gibson JM. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 279: 38353-38359, 2004.
61. Tang G, Wu L, Liang W, and Wang R. Direct stimulation of KATP channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells. Mol Pharmacol 68: 1757-1764, 2005.
62. Taniguchi S and Niki I. Significance of hydrogen sulfide production in the pancreatic b-cell. J Pharmacol Sci 116: 1-5, 2011
63. Tavintharan S, Ong CN, Jeyaseelan K, Sivakumar M, Lim SC, and Sum CF. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol 223: 173-179, 2007.
64. Tyagi N, Moshal KS, Sen U, Vacek TP, Kumar M, Hughes WM Jr., Kundu S, and Tyagi SC. H2S protects against methionine-induced oxidative stress in brain endothelial cells. Antioxid Redox Signal 11: 25-33, 2009.
65. Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, and Gollasch M. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 44: 271-276, 2004.
66. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, and Mootha VK. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 26: 343-351, 2008.
67. Wang W and Wong CW. Statins enhance peroxisome proliferator-activated receptor gamma coactivator-1a activity to regulate energy metabolism. J Mol Med 88: 309-317, 2010.
68. Wang Y, Zhao X, Jin H, Wei H, Li W, Bu D, Tang X, Ren Y, Tang C, and Du J. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 29: 173-179, 2009.
69. Warner GJ, Berry MJ, Moustafa ME, Carlson BA, Hatfield DL, and Faust JR. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J Biol Chem 275: 28110-28119, 2000.
70. Webb GD, Lim LH, Oh VM, Yeo SB, Cheong YP, Ali MY, El Oakley R, Lee CN, Wong PS, Caleb MG, Salto-Tellez M, Bhatia M, Chan ES, Taylor EA, and Moore PK. Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. J Pharmacol Exp Ther 324: 876-882, 2008.
71. Whiteman M, Li L, Rose P, Tan CH, Parkinson DB, and Moore PK. The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal 12: 1147-1154, 2010.
72. Wójcicka G, Jamroz-Wiśniewska A, Atanassova P, Chaldakov GN, Chylińska-Kula B, and Be1towski J. Differential effects of statins on endogenous H2S formation in perivascular adipose tissue. Pharmacol Res 63: 68-76, 2011.
73. Wu SY, Pan CS, Geng B, Zhao J, Yu F, Pang YZ, Tang CS, and Qi YF. Hydrogen sulfide ameliorates vascular calcification induced by vitamin D3 plus nicotine in rats. Acta Pharmacol Sin 27: 299-306, 2006.
74. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, and Nishida M. Molecular mechanisms of HDLcholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb 17: 436-451, 2010.
75. Yan SK, Chang T, Wang H, Wu L, Wang R, and Meng QH. Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells. Biochem Biophys Res Commun 351: 485-491, 2006.
76. Yang G Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, Snyder SH, and Wang R. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 322: 587-590, 2008.
77. Zagli G, Patacchini R, Trevisani M, Abbate R, Cinotti S, Gensini GF, Masotti G, and Geppetti P. Hydrogen sulfide inhibits human platelet aggregation. Eur J Pharmacol 559: 65-68, 2007.
78. Zhao W and Wang R. H2S-induced vasorelaxation and underlying cellular and molecular mechanisms. Am J Physiol Heart Circ Physiol 283: H474-H480, 2002.
79. Zhao W, Zhang J, Lu Y, and Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J 20: 6008-6016, 2001.
80. Zhao ZZ, Wang Z, Li GH, Wang R, Tan JM, Cao X, Suo R, and Jiang ZS. Hydrogen sulfide inhibits macrophage-derived foam cell formation. Exp Biol Med. 236: 169-176, 2011.